LON:AVO Advanced Oncotherapy (AVO) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Advanced Oncotherapy Stock (LON:AVO) Get Advanced Oncotherapy alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume200,000 shsAverage Volume1.27 million shsMarket Capitalization£9.50 millionP/E RatioN/ADividend Yield5.49%Price TargetN/AConsensus RatingN/A Company Overview Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom. Read More Receive AVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Advanced Oncotherapy and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVO Stock News HeadlinesOzarks Healthcare Partners with Avo to Integrate AI-Powered Decision Support in the EHROctober 18, 2024 | tmcnet.comAVO.L Regulatory NewsAugust 22, 2024 | lse.co.ukIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the analyst who flagged Nvidia in 2016 before its 37,800% run, says Musk may announce a new AI partnership any day.November 16 at 1:00 AM | Brownstone Research (Ad)Advanced Oncotherapy Share ChatJanuary 23, 2024 | lse.co.ukAdvanced Oncotherapy PLC AVODecember 9, 2023 | morningstar.comMFavourable Signals For Advanced Oncotherapy: Numerous Insiders Acquired StockJune 12, 2023 | finance.yahoo.comFavourable Signals For Advanced Oncotherapy: Numerous Insiders Acquired Stock \June 12, 2023 | finance.yahoo.comHardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to dateJanuary 27, 2023 | finanznachrichten.deSee More Headlines AVO Stock Analysis - Frequently Asked Questions How were Advanced Oncotherapy's earnings last quarter? Advanced Oncotherapy plc (LON:AVO) released its quarterly earnings data on Monday, June, 29th. The company reported GBX (9.83) EPS for the quarter, missing analysts' consensus estimates of GBX (8.90) by GBX 0.93. What other stocks do shareholders of Advanced Oncotherapy own? Based on aggregate information from My MarketBeat watchlists, some other companies that Advanced Oncotherapy investors own include Oxford Biomedica (OXB), Motif Bio (MTFB), Applied Graphene Materials (AGM), BP (BP), Bahamas Petroleum (BPC), Glencore (GLEN) and Haydale Graphene Industries (HAYD). Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryN/A Current SymbolLON:AVO CIKN/A Webwww.advancedoncotherapy.com Phone+44-20-36178728FaxN/AEmployees3,900Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£32.60 million Net MarginsN/A Pretax MarginN/A Return on Equity-67.34% Return on Assets-11.73% Debt Debt-to-Equity Ratio98.71 Current Ratio1.26 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow33.50 Book ValueGBX 14 per share Price / BookN/AMiscellaneous Outstanding Shares542,570,000Free FloatN/AMarket Cap£9.50 million OptionableNot Optionable Beta0.06 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (LON:AVO) was last updated on 8/30/2023 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Advanced Oncotherapy plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Advanced Oncotherapy With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.